HomeCardiff Oncology Announces Expanded Access Program for Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer as Follow-On to Fast Track Designation

Cardiff Oncology Announces Expanded Access Program for Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer as Follow-On to Fast Track Designation

San Diego, 09.06.2020

For the full press release: https://cardiffoncology.investorroom.com/2020-06-09-Cardiff-Oncology-Announces-Expanded-Access-Program-for-Onvansertib-in-KRAS-Mutated-Metastatic-Colorectal-Cancer-as-Follow-On-to-Fast-Track-Designation